Adoptive Cell Therapy Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-03-06　·　151 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 12.45 Bn
2033 年預估規模: USD 22.4 Bn
年複合成長率 CAGR: 12.1%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-03-06頁數 151報告編號 CMI4957

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Adoptive Cell Therapy Market, By Type (CAR-T, TCR-T, NK, TIL), By Application (Lymphoma, Leukemia, Others), By End User (Hospitals, Cancer Treatment Centers), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells (a type of immune cell) are given to a patient to help the body fight diseases, such as cancer. Types of adoptive cell therapy include chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, tumor infiltrating lymphocytes (TILs), and natural killer (NK) cells. Adoptive cell therapy involve use of immune cells that are grown in the lab in large numbers followed by administering them to the body to fight cancer. Sometimes, immune cells that naturally recognize melanoma are used, while other times they are modified to make them recognize and kill the melanoma cells. Adoptive cell therapy is also called T-cell transfer therapy, and cellular immunotherapy. Market Dynamics Key players operating in the global adoptive cell therapy market are focusing on adoption of growth strategies such as product launch, collaboration, and fundraise which are expected to drive the market growth during the forecast period. For instance, in January 2021, Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for GC012F, Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma. Moreover, in November 2019, Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment of multiple solid cancers, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company announced that they have entered into a development, license and supply agreement. This collaboration between Zelluna Immunotherapy and Glycostem Therapeutics BV will focus on the development and manufacture of allogeneic TCR guided NK cell therapies (TCR-NK’s) for the treatment of patients with cancer Key features of the study • This report provides an in-depth analysis of the global adoptive cell therapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global adoptive cell therapy market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies • Key companies covered as a part of this study include Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global adoptive cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global adoptive cell therapy market Market Segmentation • By Type o CAR-T o TCR-T o NK o TIL • By Application o Lymphoma o Leukemia o Others • By End User o Hospitals o Cancer Treatment Centers • By Region o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East & Africa  GCC Countries  Israel  Rest of Middle East & Africa • Key Players o Novartis AG o Gilead Sciences, Inc. o Castle Creek Biosciences, Inc. o Lineage Cell Therapeutics, Inc. o Transgene SA o Cellectis o ImmunityBio, Inc. o Sorrento Therapeutics, bluebird bio, Inc. o Arcellx, Sana Biotechnology, Inc. o Biodesix, Inc o Laurus Labs

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Type  Market Snapshot, By Application  Market Snapshot, By End User  Market Snapshot, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Market Trends o Key Developments o Product Approval o Collaboration/Merge/Acquisition o Regulatory Landscape o PEST Analysis o Porter’s Five Forces Analysis o Epidemiology o Robust Pipeline Analysis 4. Adoptive Cell Therapy Market, By Type, 2026 – 2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026– 2033  Segment Trends o CAR-T  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn) o TCR-T  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn) o NK  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn) o TIL  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn) 5. Adoptive Cell Therapy Market, By Application, 2026 – 2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026 – 2033  Segment Trends o Lymphoma  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn) o Leukemia  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn) 6. Adoptive Cell Therapy Market, By End User, 2026 – 2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026 – 2033  Segment Trends o Hospitals  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn) o Cancer Treatment Centers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn) 7. Adoptive Cell Therapy Market, By Region, 2026 – 2033, (USD Bn) o Introduction  Market Share Analysis, By Region, 2026 and 2033 (%)  Y-o-Y Growth Analysis, For Regions, 2026–2033  Regional Trends o North America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn) o Brazil o Mexico o Argentina o Rest of Latin America o Europe  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn) o U.K. o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn) o GCC o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)  Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 – 2033, (USD Bn) o North Africa o Central Africa o South Africa 8. Competitive Landscape o Heat Map Analysis o Market Share Analysis o Company Profile  Novartis AG o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Gilead Sciences, Inc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Castle Creek Biosciences, Inc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Lineage Cell Therapeutics, Inc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Transgene SA o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Cellectis o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  ImmunityBio, Inc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Sorrento Therapeutics o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  bluebird bio, Inc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Arcellx o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Sana Biotechnology, Inc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Biodesix, Inc o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Laurus Labs o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies o Analyst Views 9. Section o References o Research Methodology o About Us

提及公司

Novartis AGGilead Sciences, Inc.Castle Creek Biosciences, Inc.Lineage Cell Therapeutics, Inc.Transgene SACellectisImmunityBio, Inc.Sorrento Therapeutics, bluebird bio, Inc.Arcellx, Sana Biotechnology, Inc.Biodesix, IncLaurus Labs

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們